Czech Republic Pharmaceuticals and Healthcare Report Q1 2013
Jan 30th 2013, 00:00
BMI View: The recent measures proposed by the Czech Republic''s Ministry of Health will, in alllikelihood, negatively affect the Czech pharmaceutical market. The introduction of reimbursementceilings, blind bidding auctions and preferential prescribing will squeeze drugmakers'' margins and shiftsome of the burden of healthcare spending onto the private sector. The outcome of similar measures inHungary and Poland strongly supports our view that the business environment for drugmakers willworsen if these proposals are adopted. It is patients who, ultimately, will suffer.Headline Expenditure Projections?? Pharmaceuticals: CZK80.71bn (US$4.56bn) in 2011 to CZK79.76bn...
|
No comments:
Post a Comment